Inyx buys Pharmapac to enrich its offerings

By Staff Reporter

- Last updated on GMT

Related tags Drug delivery Pharmacology

In a deal worth up to $19.9m (€15.6m), US drug delivery company
Inyx has acquired contract pharmaceutical packaging firm Pharmapac,
seeking to enhance its secondary-packaging capabilities for a wide
range of dosage forms.

Pharmapac's areas of expertise in solids (tablets and capsules), semi-solids (gels), creams, liquids, sachet filling, powders and wound-care solutions will expand Inyx's capabilities in formulations and drug delivery systems.

The two companies expect growth to be derived from the cross-selling of their respective client bases, as well as the boost Inyx will receive in the drug delivery portfolio it offers to the European pharmaceutical industry.

"Pharmapac is highly profitable and a strong cash generator, and it has a network of complementary distribution and packaging customers,"​ said Inyx CEO Jack Kachkar.

"The addition of Pharmapac's dedicated 'state-of-the-art' packaging facility will enable Inyx to provide a dynamic secondary-packaging resource for a wide range of dosage forms needed to serve high-demand respiratory, allergy, dermatology and topical product sectors."

Inyx said it would retain all of Pharmapac's 200-plus present employees, including executives who will further strengthen Inyx's existing operating and technical management teams.

In fact Pharmapac's 42,000-square foot facilities in Wirral are about an hour drive from Inyx's current two UK sites also located in the North West of England.

The acquisition of Pharmapac complements Inyx's pending acquisition of a pharmaceutical production business based in Germany, the largest healthcare market in Europe.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more